natgillin/translations-raw huggingface dataset:
The CD19xCD3 bispecific single chain antibody construct for the use of any one of claims 1 to 5, followed by allogeneic hematopoietic stem cell transplantation or wherein said method replaces allogeneic hematopoietic stem cell transplantation in patients eligible for allogeneic hematopoietic stem cell transplantation. 
Konstrukt CD19xCD3 bispecifičnog jednolančanog protutijela za uporabu prema bilo kojem od zahtjeva 1 do 5, nakon čega slijedi alogena transplantacija hematopocetskih matičnih stanica ili pri čemu navedeni postupak zamjenjuje alogenu transplantaciju hematopostskih matičnih stanica pacijenata podobnih za alogenu transplantaciju hematopoetskih matičnih stanica.
The compound according to claim 7 wherein R1, R2, R3 are hydrogen; n is 0; is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Naama RJ Spoj u skladu s patentnim zahtjevom I 7, naznačen time, da su R,, R2 i Rz vodik; nje 0; Ry je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heleroarilalkila, i (NRcRp)sulfonila; a
Process according to claim 1, in which the biomass feedstock consists of at least one of the following elements: wood, cultivated plants, agricultural lignocellulosic waste, and residues of the industry for transformation of the lignocellulosic materials. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time što se sirovina biomase sastoji od najmanje jednog od sljedećih elemenata: drva, kultiviranih biljaka, poljoprivrednog lignoceluloznog otpada, ostataka iz industrije za transformaciju lignoceluloznih materijala.
Functional CB-1 inverse agonist activity of test compounds was determined in CHO-CB-1 cells using a cAMP accumulation assay. 
Funkcionalna CB-1 inverzna agonistička aktivnost ispitivanih spojeva određivana je u CHO-CB-1 stanicama primjenom CAMP akumulacijske analize.
The in vivo distribution of radiolabelled IL-2 was compared after intravenous administration of the protein either in SDS-microaggregated form or in monomeric form. 
Distribucija in vivo radioobilježenog IL-2 usporedila se nakon intravenoznog davanja proteina ili u mikroagregatnom obliku SDS ili u monomernom obliku.
Each microprocessor 6a, 6b receives the signals from respective acquisition circuit 7a, 7b, and is connected to respective telegram memory 8a, 8b and to respective RAM memory 9a, 9b. 
Svaki mikroprocesor 6a, 6b prima signale iz odnosnog akvizicijskog komunikacijskog kruga 7a, 7b i povezan je na odnosnu memoriju telegrama 8a, 8b 1 na odnosnu RAM memoriju 9, 9b.
R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; and 
Cr12-alkil, C320-heterociklil 1 Cs5.20-aril, i po izboru u odnosu na skupinu NRR', R i R' zajedno s dušikovim atomom na kojega su priključeni, tvore po izboru supstituirani 4-člani, 5-člani, 6-člani ili 7-člani heterociklički prsten;
A system for generating and maintaining a magnetic field with a field reversed configuration (FRC) comprising a confinement chamber, 
Sustav (10) za generiranje i održavanje plazme u magnetskom polju s FRC konfiguracijom povratnog polja koji obuhvaća sljedeće:
The device as defined in claim 1 for endoluminal laser ablation, further comprising at least one laser source that provides laser radiation of at least one of 1470 nm and 1950 nm, each ±30 nm, at a power of less than or equal to 10 W, wherein the proximal end of the waveguide is optically coupled to the at least one laser source, and wherein the emitting surface of the waveguide emits radiation laterally with respect to the elongated axis of the waveguide in an axially-extending, annular pattern onto the surrounding vessel wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time da nadalje sadrži barem jedan laserski izvor (424) koje omogućuje lasersko zračenje od najmanje od oko 980 nm, oko 1470 nm, te oko 1950 nm, svaki oko +/- 30 nm, na snazi od manje ili jednako do oko 10 W, pri čemu je proksimalni kraj valovoda (100, 200, 500, 600, 800, 900) optički povezan s najmanje jednim laserskim izvorom (424), i gdje emitirajuća površina (110, 210,
The water soluble taxane derivative according to claim 1, characterized in that in general formula (I-1), R1 is H, R2 is acetyl, and R3 is phenyl; 
2. - Derivat taksana topiv u vodi u skladu s patentnim zahtjevom 1, naznačen time što u općoj formuli (I-1), R' je H, R' je acetil, a R? je fenil;
A pharmaceutical formulation which is free or substantially free of a phosphate buffer and selected from the group consisting of: 
HR P20182006 T1 PATENTNI ZAHTJEVI o Farmaceutska formulacija koja je bez fosfatnog pufera i odabrana je iz skupine koju čine:
A method according to any one of the preceding claims, wherein the simulating (250) is configured to operate such that no charging or reduced charging is incurred to the sender when a message is not delivered to an existing recipient. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje je simulacija (250) podešena da funkcionira tako da ne dođe do naplate ili snižene naplate pošiljatelju kada se poruka ne pošalje postojećem primatelju.
The synthetic process is illustrated in Scheme 1 
Sintetski postupak prikazan je u Shemi 1. kB Å e A
The device as claimed in claim 1, wherein the chip (103) comprises a transparent sealing cap to cover the reaction chamber (201). 
Mikročip (10) prema zahtjevu 1, pri čemu je volumen reakcijske komore (11) unutar raspona od oko 1 ul do oko 25 ul.
Use of the metastin derivative according to (1) through (8) or a salt thereof, or a prodrug thereof to manufacture an agent for improving gonadal function. 
Uporaba derivata metastina prema zahtjevu 1 ili 2, ili njegove soli, naznačena time, da je za proizvodnju lijeka za poboljšanje gonadne funkcije.
Use according to claim 7, wherein the X-Rays radiations are of about 50 KeV to 6000 KeV. 
Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 7, pri čemu su zračenja X-zraka oko 50 KeV do 6000 KeV.
Summary of the Invention: 
Broj objave europskog patenta:
provided that the compound of formula (I) contains at least one fluorine atom, and wherein the disease or condition is selected from bone resorption, osteoporosis, vascular restenosis, diabetic retinopathy, macular degeneration, atherosclerosis, inflammation, viral disease, tumor growth, and metastasis.” 
Spoj ili preparat za upotrebu prema patentnom zahtjevu 11, naznačen time, da je bolest ili stanje odabrano iz skupine koja se sastoji od makularne degeneracije, dijabetične retinopatije (DR), makularnog edema, dijabetičnog makularnog edema (DME) i makularnog edema nakon okluzije retinalne vene (RVO).
The antibody or antigen-binding fragment thereof of any of claims 1-8, wherein the antibody or antigen-binding fragment dissociates from a human NGF polypeptide with a KD of 4 x 10-12 M. 
Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1-8, naznačen time da se antitijelo ili antigen vezujući fragment odvaja od humanog NGF polipeptida s Kp (konstantno disocijacije) od 4 x 107"M.
a parser configured to: obtain, from a bitstream, a most probable mode flag indicating whether one of candidate intra prediction modes is used to determine an intra prediction mode of a current block, and parse, from the bitstream, a mode index indicating one among candidate intra prediction modes included in a candidate list, when the most probable mode flag indicates that one of the candidate intra prediction modes is used; 
- < dobivanje iz toka bitova, zastavice najvjerojatnijeg načina, koja označava da li je upotrijebljen jedan od kandidata načina unutrašnjeg predviđanja, za određivanje načina unutrašnjeg predviđanja trenutnoga bloka; - kada zastavica najvjerojatnijeg načina označava, da je upotrijebljen jedan od kandidata načina unutrašnjeg predviđanja, raščlanjivanje indeksa načina iz toka bitova, koji ukazuje na jednog između kandidata načina unutrašnjeg predviđanja koji su uključeni u popis kandidata;
wherein in formulae (14) to (16) R1 is hydrogen or a nitrogen protecting group. 
Pf3-a) pri čemu u gornjim formulama R1 je vodikova ili dušikova zaštitna skupina.
The host cell of claim 6, wherein the cell is a mammalian cell. 
Stanica domaćin prema zahtjevu 6, naznačena time da stanica je stanica sisavca.
the reaction of a compound of the formula (X) with a compound of the formula (XI) or an N-protected derivative thereof: wherein A, E, and R1 to R5 are as defined in any one of the preceding claims, one of the groups X and Y is selected from chlorine, bromine, iodine and trifluoromethanesulphonate, and the other one of the groups X and Y is a boronate residue, for example a boronate ester or boronic acid residue, in the presence of a palladium catalyst and a base; 
H (xD (X) u prisutnosti paladijevog katalizatora i baze, gdje su A, E, i R! do R? kako su definirani u bilo kojem od zahtjeva L do 48, jedna od skupina X i Y je izabrana između klora, broma, joda i trifluorometansulfonata, a druga od skupina X i Y je boronat ester ili ostatak boronske kiseline;
Acute myeloid leukaemia. 
Akutna mijeloična leukemija.
The use of any one of claims 1 to 4, wherein said peripheral injection comprises intraperitoneal (i.p.), intramuscular (i.m.) or intravenous (i.v.) injection, preferably intravenous injection. The use of any one of claims 1 to 5, wherein said AAV vector is a human serotype AAV vector, preferably selected from serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, more preferably from AAV1, AAV2, AAV6 and AAV9, most preferably AAV9. The use of any one of claims 1 to 6, wherein the AAV vector is a pseudotyped AAV vector. 
AAV vektor koji sadrži terapijski gen, za uporabu u metodi za stvaranje terapijskog proteina ili RNA u motoričkim neuronima subjekta intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenog vektora, pri čemu je navedeni AAV vektor: dvolančani samokomplementarni AAV9 vektor, ili pseudotipizirani AAV vektor koji sadrži dvolančani samokomplementarni AAV genom deriviran iz AAV serotipa različitog od AAV9 serotipa i kapsidu deriviranu iz AAV9 kapside.
An anti-FcRn antibody or binding fragment thereof according to claim 1, wherein the antibody or binding fragment is conjugated to starch, albumin, or polyethylene glycol. 
Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema bilo kojem patentnom zahtjevu od 1 do 3, naznačen time, što je antitijelo ili vezujući fragment konjugiran na polimer, primjerice odabran iz škroba, albumina i polietilenglikola.
A pharmaceutical composition comprising the bispecific antibody or antibody fragment thereof according to any one of claims I to 4 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži bispecifično antitijelo ili njegov bispecifični fragment antitijela prema bilo kojem zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač.
The sample was spun at 15.0 kHz, and a total of 2048 scans were collected with a recycle delay of 20 seconds. 
Uzorak je rotiran na 15.0 kHz, te je ukupno sakupljeno 2048 skenova, uz zadršku od 20 sekundi.
Composition according to one of the preceding claims, characterized in that the proportion of Salix alba extract is in the range of 0.001 % (w/w) and 10 % v, preferably between 0.01 % (w/w) and 5 % (w/w), based on the total mass of the preparation. Composition according to one of the preceding claims, characterized in that the ratio between Salix alba extract and 1,2-Decanediol is between 1:10 and 10:1; preferably between 1:5 and 5:1, more preferably 1:1. Surfactant system, water-in-oil emulsion, oil-in-water emulsion, serum, gel, oil, aqueous solution, hydroalcoholic solution, anhydrous sticks, compact founding powder, lotion, milk, suncream, after sun product or camouflage product.customary auxiliaries and additives. 
1 10% (tež./tež.), po mogućnosti između 0,01% (tež./tež.) 15% (tež./tež.), na osnovi ukupne mase pripravka. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pripravak u obliku surfaktantnog sustava, emulzije vode u ulju, emulzije ulja u vodi, seruma, gela, ulja, vodene otopine, hidroalkoholne otopine, bezvodnih štapića, kompaktnog temeljnog pudera, losiona, mlijeka, kreme za sunčanje, proizvoda nakon sunčanja ili proizvoda za korekturu.
Due to their mechanical strength properties the nano-fibrillar cellulose gels can be advantageously used in applications such as in material composites, plastics, paints, rubber, concrete, ceramics, adhesives, food, or in wound-healing applications. 
Upotreba gela od nanofibrilarne celuloze u skladu s bilo kojim od patentnih zahtjeva 15 ili 16, naznačena time što je gel namijenjen primjenama poput kompozitnih materijala, plastika, boja, gume, betona, keramike, ljepila, hrane, ili u primjenama kod zacjeljivanja rana.
These commodities may be recycled after their use. 
Ovi proizvodi mogu se reciklirati nakon uporabe.
This allows for filler content, e.g., as high as 77-87% by weight. 
To omogućuje da sadržaj punila iznosi npr. od 77-87% po masi.
Use of a compound according to claim 11 or 12 characterised in that R3 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-6-alkyl, preferably methyl, C1-6-alkoxy, preferably methoxy, C1-6-alkoxy-C1-6-alkoxy, preferably 2-methoxy-ethoxy, trifluoromethyl and trifluoromethoxy. 
Upotreba spoja, koji je dan patentnim zahtjevom 11 ili 12, naznačena time, da R* i R* su neovisno odabrani iz skupine koja vodik, halogen, C;-alkil, preferirano metil, Ci.g-alkoksi, preferirano metoksi, C;.g-alkoksi-C;.4- alkoksi, preferirano 2-metoksi-etoksi, trifluorometil i trifluorometoksi.
The capsule according to claim 1 or 2, wherein the valve means are designed to block the flow path in an essentially airtight fashion. 
Kapsula u skladu s patentnim zahtjevom 1 ili 2, naznačena time što ventil (15) je tako osmišljen da uglavnom hermetički čvrsto blokira protok.
Further, any cycloalkyl may be optionally substituted through any available carbon atoms with one or more groups selected from hydrogen, halo, haloalkyl, alkyl, alkoxy, haloalkyloxy, hydroxyl, alkenyl, alkynyl, aryl, aryloxy, heteroaryl, heteroaryloxy, arylalkyl, heteroarylalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents. 
Dalje, svaki cikloalkil može biti opcijski supstituiran putem bilo kojih dostupnih ugljikovih atoma sa jednom ili više skupina koje su odabrane od vodik, halo, haloalkil, alkil, alkoksi, haloalkiloksi, hidroksil, alkenil, alkinil, aril, ariloksi, heteroaril, heteroariloksi, arilalkil, heteroarilalkil, alkilamido, alkanoilamino, okso, acil, arilkarbonilamino, amino, nitro, cijano, tiol i/ili alkiltio i/ili bilo kojeg od alkilnih supstituenata.
administering to the patient a first buprenorphine-containing transdermal patch for a first dosing period that is no longer than about 5 days; 
(a) davanje navedenom pacijentu prvog transdermalnog oblika doziranja buprenorfina u prvom periodu doziranja koji ne traje duže od približno pet 5 dana;
Method of definition 7 wherein the sponge is applied to said injury together with a buffer solution, e.g. a bicarbonate solution, e.g. on a gauze. 
Spužva prema zahtjevu 7, naznačena time da se spužva primjenjuje na navedenu ozljedu zajedno s puferskom otopinom, naročito otopinom bikarbonata, poželjno na gazi.
a phenyl group, substituted or unsubstituted by one or two halogen atoms, or by one or two methyl groups, or by one or two methoxy groups, or by a cyano group, 
- fenilna skupina, supstituirana ili nesupstituirana jednim ili dvama atomima halogena ili jednom ili dvjema metilnim skupinama ili jednom ili dvjema metoksilnim skupinama ili cijano-skupinom,
A colloidal suspension according to any of the embodiments 20-26, wherein said nanocrystalline particles comprises a photocatalyst comprising the anatase form of titania or a modified form thereof in a concentration of least 10 wt%, and said one or more dispersants comprises an amine such as triethylamine (TEA) in a concentration in the range 1-10 wt %and monopropylene glycol in a concentration in the range 10-20 wt %. 
Koloidna suspenzija prema bilo kojem od patentnih zahtjeva 12-14, naznačena time da navedene nanokristalinične čestice sadrže fotokatalizator koji sadrži anatazni oblik titanijevog dioksida ili njegov modificiran oblik u koncentraciji od najmanje 10 težinskih %, te navedeno jedno ili više disperzijskih sredstava sadrži amin kao što je trietilamin (TF.A) u koncentraciji u rasponu od 1-10 težinskih % i monopropilen glikol u koncentraciji u rasponu od 10-20 težinskih %.
A preferred maximum thickness of the veneer is 4 mm. 
Poželjna maksimalna debljina furnira je 4 mm.
The composition for use according to claim 23, wherein therapeutically effective amount of crenolanib or a salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed acute myeloid leukemia (AML) pediatric subject, tc maintain remission, or a relapsed or refractory acute myeloid leukemia (AML) pediatric subject. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili pedijatrijskom subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
Optoisolator 17, which permits passage of the output data, is supplied with voltage Vdc by watchdog circuit 18, which is enabled by enabling signals from microprocessors 6a, 6b. 
Optoizolator 17, koji dopušta prolaz izlaznih podataka, se napaja naponom Va, pomoću kontrolnog (watchdog) električkog kruga 18, koji se osposobljava omogućujućim signalima iz mikroprocesora 6a, 6b.
A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity, comprising administering to the subject an effective amount of a compound of claim 1, wherein the disease, disorder, or medical condition mediated by orexin receptor activity is a sleep disorder, a metabolic disorder, a neurological disorder, acute heart failure, ulcers, irritable bowel syndrome, diarrhea, gastroesophageal reflux, a mood disorder, post-traumatic stress disorder, a panic disorder, an attention deficit disorder, a cognitive deficiency, or substance abuse. 
23. Spoj prema bilo kojem od zahtjeva 1 do 21 naznačen time daje za upotrebu za liječenje bolesti, poremećaja ili medicinskog stanja, u kojem je bolest, poremećaj ili medicinsko stanje poremećaj spavanja, metabolički poremećaj, neurološki poremećaj, aritmija, akutni prestanak rada srca, sindrom iritabilnih crijeva, proljev, gastroezofagusni refluks, poremećaj raspoloženja, poremećaj posttraumatskog stresa. pažnje dostatka
In another embodiment the invention is a pharmaceutical composition according to any of statements 11 to 14, characterized by containing at least another active ingredient, preferably a chemotherapeutic active ingredient, as a combination for simultaneous, separate or sequential administration. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14 i najmanje jedan drugi aktivni sastojak, po mogućnosti kemoterapijski aktivni sastojak, naznačeni time što su namijenjeni istodobnoj, odvojenoj ili uzastopnoj primjeni.
L represents the chain of the substructure III: 
Datum objave europske prijave patenta:
Ingested surfactants may facilitate penetration or absorption of potentially toxic or pathogenic compounds, which in turn may result In adverse effects on the other organs (Lieberman, H.A., Rieger, M.M. 
Progutani surfaktanti mogu olakšati unos ili apsorpciju potencijalno toksičnih ili patpgenih spojeva, koji naizmjence mogu rezultirati u suprotnom učinku na ostale organe (Lieberman, H.A., Rieger, M.M.
It is therefore the object of the present invention to provide a nail topical formulation which overcomes the above noted disadvantages, which can be easily formulated, prepared and stored and provides good nail restructuring, hardening and strengthening effect. 
Stoga je predmet ovog izuma naći topikalnu formulaciju koja svladava gore navedene nedostatke, koja se može lako formulirati, proizvesti i uskladištiti, te pruža dobro restrukturiranje nokta, učinak očvršćivanja i ojačavanja.
Nalmefene for use according to any of claims 1-8, wherein said nalmefene is to be used as-needed. 
Nalmefen za uporabu prema zahtjevu 7, gdje je količina nalmefena 18 mg.
The method of claim 7, wherein the composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 23, naznačen time što je u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
Antibody according to claim 1 to 2, whereby the antibody consists of an antigen-binding region that binds specifically to or has a high affinity of for one or more regions of PRLR, whose amino acid sequence is depicted by SEQ ID NO: 70 and human polymorphic variants of SEQ ID NO: 70, amino acid position 1 to 210, whereby the affinity is at least 100 nM, preferably less than about 100 nM, more preferably less than about 30 nM, even more preferred with an affinity of less than about 10 nM, or even more preferred with an affinity of less than 1 nM. 
Antitijelo prema zahtjevu 1 do 2, naznačeno time da se antitijelo sastoji od regije koja veže antigen koja se specifično veže na ili ima visoki afinitet za jednu ili više regija od PRLR, čija je sekvenca amino kiseline prikazana sa SEQ ID NO: 70 i ljudskim polimorfnim varijantama iz SEQ ID NO: 70, položajem amino kiseline 1 do 210, pri čemu je afinitet barem 100 nM, poželjnije s afinitetom od manje od oko 100 nM, poželjnije s afinitetom od manje od oko 30 nM, čak još poželjnije s afinitetom od manje od oko 10 nM, ili čak još poželjnije s afinitetom od manje od 1 nM.
The compound of claim 5 wherein R2a, R2b and R2c are independently selected from the group consisting of: 
Spoj prema patentnom zahtjevu 9, naznačen time što su R2a, R2b i R2c nezavisno izabrani iz grupe koju čine:
Compounds of formula XVI wherein L is an activated group such as chlorine, bromine and the like and Z is O or N are commercially available, or can be synthesized by those skilled in the art. 
Spojevi formule XVI gdje je L aktivirana skupina kao što je klor, brom i slično i Z je 0 ili N komercijalno su dostupni ili ih mogu sintetizirati osobe iz struke.
heating the bonding material to non-removably secure the fitment to the container and thereby render the product tamper-evident, wherein step (d) includes heat-bonding a heat-activated ceramic or glass bonding compound, solder glass material and/or a ring of soda lime glass of the bonding material between the interior surface of the neck of the container and the radially outer surface of the fitment. 
(d) grijanje vezivnog materijala kako bi se neuklonjivo pričvrstilo nastavak na spremnik 1 tako omogućilo da se vidi ako je na proizvodu došlo do neovlaštenog rukovanja, gdje korak (d) uključuje povezivanje grijanjem toplinom aktiviranog keramičkog 1li staklenog vezivnog spoja, lemljenje staklenog materijala i/ili prstena od običnog stakla kao vezivnog materijala između unutarnje površine grla spremnika i radijalne vanjske površine nastavka.
CD19 as a first antigen and CD22 as a second antigen; 
CD19 kao prvi antigen i CD22 kao drugi antigen;
Products containing the following A) and B): 
Preparati koji sadrže sljedeće stavke A) i B):
The pharmaceutical composition for use according to claim 12, wherein said cancer is colorectal cancer. 
Farmaceutski sastav za uporabu prema zahtjevu 13, gdje je karcinom kolorektalni karcinom.
Table 1: Peptides of the present invention 
Datum objave europske prijave patenta: